RAC Regulatory Strategic Planning 3

Question 1

Which tool is most useful for proactively identifying regulatory risks before a product submission?

Accepted Answer

FMEA (Failure Mode and Effects Analysis) of the regulatory strategy

Answer

FMEA applied to regulatory strategy systematically identifies potential failure modes in the regulatory plan and their impact on approval timelines.

Question 2

A company seeks approval in both the EU and US simultaneously. The primary benefit of using the ICH CTD format is:

Accepted Answer

It provides a harmonized submission structure accepted by both FDA and EMA

Answer

The ICH CTD (Common Technical Document) provides a standardized format accepted by FDA, EMA, and other ICH member agencies, reducing duplication in preparing dossiers.

Question 3

When should a regulatory strategy be formally reassessed during product development?

Accepted Answer

At predefined decision points and when significant new data emerge

Answer

Regulatory strategy should be reassessed at defined decision gates (e.g., end-of-Phase 2) and whenever significant new clinical, safety, or competitive data emerge.

Question 4

Which FDA program is specifically designed to expedite development and review of drugs for serious conditions where preliminary evidence shows advantage over available therapy?

Accepted Answer

Fast Track Designation

Answer

Fast Track Designation is designed to facilitate development and expedite review of drugs for serious conditions that demonstrate potential to address unmet medical needs.

Question 5

In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:

Accepted Answer

To gain EMA guidance on data requirements before a marketing authorization application

Answer

EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.

(RAC) Regulatory Affairs Certification Practice Test

(RAC) Regulatory Affairs Certification Practice Test

RAC Regulatory Strategic Planning 3